NCT02090543View on ClinicalTrials.gov

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

CompletedOBSERVATIONAL
Enrollment

647

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Atrial Fibrillation
Interventions
DRUG

Phenprocoumon (Marcumar)

common use, no requirements (real life situation)

DRUG

Rivaroxaban (Xarelto, BAY-59 7939)

common use, no requirements (real life situation)

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY

NCT02090543 - BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies | Biotech Hunter | Biotech Hunter